Epoch Investment Partners’s Corcept Therapeutics CORT Stock Holding History

Epoch Investment Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-816,652	Closed	-$28.4M	–	243
2025 Q4	$28.4M	Sell	816,652 -30,452	-4%	-$2.39M	0.16%	165
2025 Q3	$70.4M	Buy	847,104 +81,700	+11%	+$5.91M	0.39%	99
2025 Q2	$56.2M	Buy	+765,404	New	+$55.5M	0.29%	125
2022 Q4	–	Sell	-1,115,854	Closed	-$28.6M	–	423
2022 Q3	$28.6M	Buy	1,115,854 +36,107	+3%	+$966K	0.19%	167
2022 Q2	$25.7M	Buy	1,079,747 +9,689	+0.9%	+$211K	0.15%	185
2022 Q1	$24.1M	Sell	1,070,058 -120,312	-10%	-$2.56M	0.12%	200
2021 Q4	$23.6M	Buy	1,190,370 +260,964	+28%	+$5.29M	0.12%	195
2021 Q3	$18.3M	Buy	929,406 +200,987	+28%	+$4.21M	0.1%	206
2021 Q2	$16M	Buy	728,419 +558,623	+329%	+$12.4M	0.09%	208
2021 Q1	$4.04M	Buy	+169,796	New	+$4.53M	0.02%	286

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Epoch Investment Partners's CORT Position: Q1 2026 in Review

Epoch Investment Partners sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 816,652 shares — an estimated $28.4M sold.

Epoch Investment Partners first reported a position in CORT in Q1 2021 and held it in 10 quarters. The position peaked at $70.4M in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Epoch Investment Partners reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Epoch Investment Partners sold 816,652 Corcept Therapeutics shares in Q1 2026, an estimated $28.4M.
Epoch Investment Partners first reported a position in Corcept Therapeutics in Q1 2021 and held it in 10 quarters.
Epoch Investment Partners's Corcept Therapeutics position peaked at $70.4M in Q3 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Epoch Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.